CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Lithium Carbonatedrug
Likely dose
Lithium Carbonate 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01259388
NCT01259388Phase 2Completed
CompareCT.gov

A Pilot Trial of Lithium in Progressive Multiple Sclerosis

VA Office of Research and Development·interventional·Posted Dec 14, 2010·Updated Sep 10, 2019

In Brief

A Phase 2 clinical trial evaluating Lithium Carbonate for Multiple Sclerosis. Completed, enrolled 23 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 14, 2010
Enrollment StartMay 1, 2011
Primary CompletionAug 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.5 years ago

Interventions

Lithium Carbonatedrug

Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.